Summary The goal of Administrative Core in Phase 2 is to continue centralizing and managing resources necessary to enhance the success of the COBRE on Host-pathogen Interactions (HPI). Building on the success of Phase 1, this Core will provide support to investigators focused on determining the mechanisms underlying immune modulations in the host upon interaction with various microbes to identify possible treatments for devastating inflammatory diseases. Specifically, the concerted effort will focus on (1) expanding the research enterprise of this center by supporting and recruiting junior investigators working on host-microbe interactions that are central to human health and diseases; (2) facilitating productive scientific interactions by organizing networking opportunities through annual symposium and seminar series ; (3) providing an individualized and tailored mentoring program for each investigator; 4) providing oversight and support for mentoring programs through Internal and External Advisory Committees with regular meetings; 5) raising the national profile of the group by providing cutting edge infrastructural support; 6) establishing a new Computational Data Analysis Core facility to provide cutting-edge bioinformatics analytical and interpretative support for the group; 6) providing administrative support to the existing Cores (Histology, Imaging and Flow Cytometry; and 7) fostering collaboration between the other North Dakota COBRE, INBRE and CTR DaCCoTA grant supported groups and between individuals in the respective groups. Successful completion of these goals in Phase 2 of our COBRE will elevate this center to a nationally recognized level with a group dedicated to understanding various aspects of host-microbe interactions in human health and disease. With the recent funding of a Phase 2 Epigenetics COBRE and a Phase I Clinical Translational Research Center DaCCoTA, our HPI COBRE Phase 2 has an unprecedented opportunity at hand to execute high-quality, cutting edge research of immense therapeutic and clinical potential.